Novel therapies are changing treatment paradigms in metastatic prostate cancer

[1]  H. Mischak,et al.  Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer , 2020, Diagnostics.

[2]  F. Saad,et al.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[3]  P. Nelson,et al.  Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies , 2020, PloS one.

[4]  I. Taylor,et al.  First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). , 2020 .

[5]  T. Tammela,et al.  Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .

[6]  M. Stockler,et al.  TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). , 2020 .

[7]  J. Bono,et al.  KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). , 2020 .

[8]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[9]  N. Agarwal,et al.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. , 2020, JCO precision oncology.

[10]  E. Heath,et al.  An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer , 2020, Molecular Cancer Therapeutics.

[11]  L. Klotz,et al.  A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. , 2020, Clinical genitourinary cancer.

[12]  C. Pezaro.  PARP inhibitor combinations in prostate cancer , 2020, Therapeutic advances in medical oncology.

[13]  P. Kantoff,et al.  Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry , 2020, Prostate Cancer and Prostatic Diseases.

[14]  S. Park,et al.  Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010. , 2020 .

[15]  D. Petrylak,et al.  Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921. , 2020 .

[16]  A. Chinnaiyan,et al.  CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. , 2020, JCO precision oncology.

[17]  A. Tafreshi,et al.  KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). , 2020 .

[18]  M. Heck,et al.  Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best? , 2020, Urologic oncology.

[19]  A. Chinnaiyan,et al.  Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment , 2020, Neoplasia.

[20]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[21]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Collette,et al.  Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. , 2019, JAMA oncology.

[23]  N. Tunariu,et al.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[24]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Murphy,et al.  Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[26]  E. Small,et al.  Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. , 2019, Clinical genitourinary cancer.

[27]  K. Rahbar,et al.  Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics , 2019, The Journal of Nuclear Medicine.

[28]  M. Hofman,et al.  Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies , 2019, Prostate Cancer and Prostatic Diseases.

[29]  C. Drake,et al.  Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD , 2019, Annals of Oncology.

[30]  B. Chauffert,et al.  A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) , 2019, Annals of Oncology.

[31]  A. Bryce,et al.  Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses , 2019, Annals of Oncology.

[32]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[33]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Harrison,et al.  Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer , 2019, Cancer medicine.

[35]  N. Masumori,et al.  The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan , 2019, Current medical research and opinion.

[36]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[37]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[38]  M. Morris,et al.  VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). , 2019 .

[39]  C. Robson,et al.  A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities , 2019, Nucleic acids research.

[40]  D. Siemens,et al.  The Tumor Immune Contexture of Prostate Cancer , 2019, Front. Immunol..

[41]  P. Kantoff,et al.  Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[43]  P. Kantoff,et al.  Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade , 2019, JAMA oncology.

[44]  Yujing Li,et al.  Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II , 2018, Nature Communications.

[45]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[46]  A. Hotson,et al.  A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models , 2018, Cancer Immunology Research.

[47]  C. Crews,et al.  Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance , 2018, Communications Biology.

[48]  F. Saad,et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.

[49]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[50]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[51]  E. Corey,et al.  A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening , 2018, Clinical Cancer Research.

[52]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[53]  Bruce Montgomery,et al.  Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Tatematsu,et al.  Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy , 2017, Front. Immunol..

[55]  S. Tavaré,et al.  Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer , 2017, Nature Communications.

[56]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[57]  C. Crews,et al.  Targeted protein degradation by PROTACs☆ , 2017, Pharmacology & therapeutics.

[58]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[59]  Kathy Willowson,et al.  Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy , 2017, Journal of medical radiation sciences.

[60]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Lenis,et al.  Immunotherapy for the Treatment of Urothelial Carcinoma , 2017, The Journal of urology.

[62]  Y. Pommier,et al.  Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.

[63]  O. Sartor.  Isotope Therapy for Castrate-Resistant Prostate Cancer: Unique Sequencing and Combinations. , 2016, Cancer journal.

[64]  Charles G. Drake,et al.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer , 2016, Oncotarget.

[65]  B. Robinson,et al.  Immunotherapy for lung cancer , 2016, Respirology.

[66]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[67]  C. Crews,et al.  Small-Molecule PROTACS: New Approaches to Protein Degradation. , 2016, Angewandte Chemie.

[68]  J. Aragon-Ching,et al.  Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer , 2016, Clinical Medicine Insights. Oncology.

[69]  M. Atkins.  Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. , 2015, Seminars in Oncology.

[70]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[71]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[72]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[73]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[74]  A. Bryant,et al.  Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. , 2015, The Cochrane database of systematic reviews.

[75]  U. Haberkorn,et al.  [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  Sten Nilsson,et al.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. , 2014, The Lancet. Oncology.

[77]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[78]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[79]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[80]  M. Sanford.  Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer , 2013, Drugs.

[81]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[82]  E. Antonarakis,et al.  Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Ashworth,et al.  Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  M. Harrison,et al.  Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease , 2013, Cancer management and research.

[85]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[86]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[87]  J. D. de Bono,et al.  New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway , 2011, Clinical Cancer Research.

[88]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[89]  M. Jasin,et al.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis , 2010, Nature Reviews Molecular Cell Biology.

[90]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[91]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[92]  P. Ell,et al.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.

[93]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[94]  R. Lerski,et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[96]  J. Smart.  THE USE OF P32 IN THE TREATMENT OF SEVERE PAIN FROM BONE METASTASES OF CARCINOMA OF THE PROSTATE. , 1965, British journal of urology.